HRP20130969T1 - Spojevi spiropiperidona kao antagonisti receptora orl-1 - Google Patents

Spojevi spiropiperidona kao antagonisti receptora orl-1 Download PDF

Info

Publication number
HRP20130969T1
HRP20130969T1 HRP20130969AT HRP20130969T HRP20130969T1 HR P20130969 T1 HRP20130969 T1 HR P20130969T1 HR P20130969A T HRP20130969A T HR P20130969AT HR P20130969 T HRP20130969 T HR P20130969T HR P20130969 T1 HRP20130969 T1 HR P20130969T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
acceptable salt
methyl
fluorine
compound according
Prior art date
Application number
HRP20130969AT
Other languages
English (en)
Croatian (hr)
Inventor
Ana Belen Benito Collado
Nuria Diaz Buezo
Alma Maria Jimenez-Aguado
Celia Lafuente Blanco
Maria Angeles Martinez-Grau
Concepcion Pedregal-Tercero
Miguel Angel Toledo Escribano
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20130969T1 publication Critical patent/HRP20130969T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20130969AT 2009-11-16 2010-11-12 Spojevi spiropiperidona kao antagonisti receptora orl-1 HRP20130969T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382245 2009-11-16
US29862810P 2010-01-27 2010-01-27
PCT/US2010/056449 WO2011060217A1 (en) 2009-11-16 2010-11-12 Spiropiperidine compounds as orl-1 receptor antagonists

Publications (1)

Publication Number Publication Date
HRP20130969T1 true HRP20130969T1 (hr) 2013-11-22

Family

ID=41800752

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20130969AT HRP20130969T1 (hr) 2009-11-16 2010-11-12 Spojevi spiropiperidona kao antagonisti receptora orl-1

Country Status (18)

Country Link
US (1) US20120214784A1 (https=)
EP (1) EP2501704B1 (https=)
JP (1) JP5723381B2 (https=)
KR (1) KR101368130B1 (https=)
CN (1) CN102666550B (https=)
AU (1) AU2010319400B2 (https=)
BR (1) BR112012011710A2 (https=)
CA (1) CA2781041C (https=)
DK (1) DK2501704T3 (https=)
EA (1) EA020391B1 (https=)
ES (1) ES2436241T3 (https=)
HR (1) HRP20130969T1 (https=)
MX (1) MX2012005690A (https=)
PL (1) PL2501704T3 (https=)
PT (1) PT2501704E (https=)
RS (1) RS53017B (https=)
SI (1) SI2501704T1 (https=)
WO (1) WO2011060217A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106883246B (zh) * 2009-12-04 2020-05-29 桑诺维恩药品公司 多环化合物及其使用方法
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之orl-1受體拮抗劑
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
CA3032141A1 (en) 2016-07-29 2018-02-01 Vadim ALEXANDROV Compounds and compositions and uses thereof
UA125519C2 (uk) 2016-07-29 2022-04-13 Суновіон Фармасьютікалз Інк. Сполуки і композиції і їх застосування
KR20190037305A (ko) 2016-08-10 2019-04-05 바이엘 크롭사이언스 악티엔게젤샤프트 해충 방제제로서의 치환된 2-헤테로시클릴 이미다졸릴-카르복스아미드
IL268694B2 (en) 2017-02-16 2023-10-01 Sunovion Pharmaceuticals Inc Treatment of schizophrenia
DK3589637T3 (da) * 2017-03-02 2021-06-14 Lilly Co Eli Forbindelser, der er anvendelige til inhibering af ROR-GAMMA-T
PL3589638T3 (pl) 2017-03-02 2021-09-27 Eli Lilly And Company Związki użyteczne do hamowania ror-gamma-t
BR112020001433A2 (pt) 2017-08-02 2020-07-28 Sunovion Pharmaceuticals Inc. compostos de isocromano e usos dos mesmos
EA202091945A1 (ru) 2018-02-16 2021-01-18 Суновион Фармасьютикалз Инк. Соли, кристаллические формы и способы их получения
TWI848031B (zh) 2018-12-17 2024-07-11 美商維泰克斯製藥公司 Apol1抑制劑及其使用方法
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
EP3766879A1 (en) 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
CN115734785A (zh) 2020-04-14 2023-03-03 桑诺维恩药品公司 (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症
WO2021252863A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
IL300298B2 (en) 2020-08-26 2025-06-01 Vertex Pharma Inhibitors of apol1 and methods of using same
CN119343353A (zh) * 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003235912A1 (en) 2002-05-10 2003-11-11 Taisho Pharmaceutical Co., Ltd. Spiro-ring compound
WO2005016913A1 (en) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
CA2563164A1 (en) * 2004-03-29 2005-10-06 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US7655670B2 (en) * 2005-06-02 2010-02-02 Janssen Pharmaceutica N.V. 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators

Also Published As

Publication number Publication date
EA020391B1 (ru) 2014-10-30
DK2501704T3 (da) 2013-10-14
EA201290355A1 (ru) 2012-10-30
AU2010319400A1 (en) 2012-06-07
CA2781041C (en) 2015-01-06
KR101368130B1 (ko) 2014-02-27
CA2781041A1 (en) 2011-05-19
CN102666550A (zh) 2012-09-12
PL2501704T3 (pl) 2014-02-28
ES2436241T3 (es) 2013-12-27
MX2012005690A (es) 2012-06-13
PT2501704E (pt) 2013-12-05
WO2011060217A1 (en) 2011-05-19
EP2501704A1 (en) 2012-09-26
US20120214784A1 (en) 2012-08-23
SI2501704T1 (sl) 2013-11-29
RS53017B (sr) 2014-04-30
AU2010319400B2 (en) 2013-12-19
JP5723381B2 (ja) 2015-05-27
EP2501704B1 (en) 2013-09-18
CN102666550B (zh) 2015-07-15
KR20120082927A (ko) 2012-07-24
JP2013510870A (ja) 2013-03-28
BR112012011710A2 (pt) 2016-03-01

Similar Documents

Publication Publication Date Title
HRP20130969T1 (hr) Spojevi spiropiperidona kao antagonisti receptora orl-1
HRP20130967T1 (hr) Spojevi spiropiperidona kao antagonisti receptora orl-1
JP2013510870A5 (https=)
HRP20170363T1 (hr) Derivati piridina kao inhibitori kinaze pregrađene prilikom transfekcije (ret)
US20230116233A1 (en) Compounds And Compositions As Protein Kinase Inhibitors
JP2016516026A5 (https=)
SI2978752T1 (en) 6- (5-Hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as inhibitors of PHD
NZ597533A (en) Apoptosis signal-regulating kinase inhibitors
PE20140570A1 (es) Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
HRP20200781T1 (hr) DERIVATI PIRAZOLO[1,5-a]PIRAZIN-4-ILA KAO INHIBITORI JAK
RU2015143430A (ru) Новые соединения и фармацевтические композиции, их содержащие, для лечения воспалительных расстройств
MX2020005874A (es) Acidos carbamoil ciclohexilicos n-enlazados a pirazol como antagonistas de receptores del acido lisofosfatidico (lpa).
SI2989100T1 (en) NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6
RU2014105624A (ru) Соединения индазола, способ их применения и фармацевтическая композиция
JP2016528212A (ja) 複素芳香環−ベンジル−アミド−サイクルコアを含むオートタキシン阻害剤
HRP20180382T1 (hr) Inhibitori protein kinaze
HRP20120738T1 (hr) Inhibitori kinaza akt i p70 s6
AR080894A1 (es) Compuestos derivados de 2,8-diaza-espiro-[4,5]decano-1,7-diona, proceso para prepararlos, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de la obesidad, dislipidemia y diabetes.
RU2011125314A (ru) Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в
NZ603777A (en) Bicyclic compound derivatives and their use as acc inhibitors.
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
CA3005918A1 (en) Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
CN109790158A (zh) 作为jak抑制剂杂环化合物,该化合物的盐类及其治疗用途
RU2020114670A (ru) Бициклические соединения для применения в качестве ингибиторов rip1 киназы
RU2015148766A (ru) Комбинации лигандов альфа-2 адренорецептора и сигма рецептора